RudaCure (CEO Yongho Kim), una empresa especializada en el desarrollo de tratamientos para trastornos sensoriales, fue seleccionada como an Incheon Outstanding Company (Promising Enterprise) at the '2025 Incheon SME Premios and Outstanding Enterprise Certification Ceremony' hosted by Incheon Metropolitan City and organized by Incheon Technopark on the 12th, solidifying its position as a growing company in the biofarmacéutico desarrollo sector.
Founded in 2018, RudaCure ha sido dedicated to developing innovador drugs that directly and indirectly modulate the TRPV1 (Transient Receptor Potential Vanilloid 1) canal iónico, offering new tratamiento options for pacientes suffering from trastornos sensoriales such as enfermedad de ojo seco and dolor crónico.
RudaCure's core tecnología is a novel drug plataforma that directly and indirectly modulates the TRPV1 canal iónico, which regulates pain, inflammation, and temperature sensation. TRPV1 is expresó in sensory nerves and plays a crucial role in pain signal transmission and inflammatory responses. By effectively modulating this channel, RudaCure está desarrollando innovador drugs capable of treating various trastornos sensoriales. La empresa's pipeline insignia, tratamiento de la enfermedad de ojo seco 'RCI001,' utilizes a mechanism that suppresses inflammatory activation through TRPV1 downstream signal modulation. Unlike existing tratamientos, it demonstrates powerful antiinflamatorio and efectos antioxidantees, showing therapeutic resultados within 4 weeks along with confirmó increases in producción lagrimal. Notablemente, it ha sido reconocida por overcoming major efectos secundarios associated with steroid-based tratamientos, including elevated presión intraocular, hyperemia, hemorrhage, and burning sensation upon instillation.
RudaCure firmó two transferencia de tecnología acuerdos with Hanlim Pharmaceutical totaling KRW 20 billion in 2021 and 2022, gaining reconocimiento for RCI001's technical excellence. In July 2025, la empresa logró FDA Phase 2 IND (Investigational New Drug) aprobación, with nacional Phase 2 ensayo clínicos planned for 2026. La empresa también expanding into the farmacéutico veterinario mercado with a KRW 50 billion contrato with a French global fármaco veterinario developer.
The tratamiento del dolor crónico 'RCI002' is a dual-target analgésico no narcótico that simultaneously targets TRPV1 and MOR (Mu-Opioid Receptor). In estudios preclínicos, it demostró prolonged eficacia at concentrations 650 times lower than existing tratamientos with no efectos secundarios, and is applicable to various trastornos sensoriales including dolor neuropático, dolor inducido por quimioterapia, and dolor diabético without the addiction risk of analgésicos narcóticos.
Behind RudaCure's selección as an outstanding company is not only its excellent tecnología but also its stable organizational culture. La empresa has fostered an environment where empleados grow together based on its 3C core values: Creativity, Collaboration, and Challenge.
La empresa offers various financial incentives including stock options, performance bonuses, and long-service allowances, along with flexible work culture such as liberal use of anual leave and casual dress code. It also actively apoyos employee self-desarrollo through education expense subsidies and professional skill enhancement training. Como resultado, la empresa maintains a low turnover rate, and empleados are moving toward the goal of innovador desarrollo de fármacos as One Team, backed by high workplace satisfaction and pride.
RudaCure has consistently been reconocido for its organizational excellence, being seleccionada as a Talent-Nurturing SME, Outstanding Job Invention Compensation Company, and Work Innovación Excellence Company in 2022. In 2023, it fue seleccionada para the Ministry of Employment and Labor's Strong Small Enterprise programa and the Ministry of SMEs and Startups' Startup Leap Package apoyo programa. In 2024, it fue seleccionada para the Baby Unicorn 200 Development Program, demonstrating its crecimiento potential. La empresa has raised over KRW 16 billion in total inversión through Serie A (KRW 6 billion) and Serie B (KRW 10 billion), strengthening its I+D capabilities. Through transferencia de tecnología acuerdos with Hanlim Pharmaceutical and a French farmacéutico veterinario developer, la empresa ha firmado contratos totaling over KRW 70 billion, and actualmente está discussing transferencia de tecnología for tratamiento del dolor RCI002 with multiple overseas empresas. Continuous ingresos crecimiento and transferencia de tecnología logros further enhance la empresa's desarrollo potential.
CEO Yongho Kim of RudaCure is an expert who has realizó over 15 years of basic medical investigación on pain and trastornos sensoriales as a professor at Gachon University College of Medicine. La empresa continues to secure globally competitive talent, including the recruitment of Research Director Jiyoon Shin to enhance desarrollo de fármacos efficiency using AI.
El CEO Kim declaró: "This selección as an Incheon Outstanding Company is a reconocimiento of RudaCure's I+D capabilities and innovador tecnología," adding, "Based on our proprietary TRPV1 modulation tecnología plataforma, we proporcionará more effective and safer tratamiento options for pacientes suffering from trastornos sensoriales and grow into a globally competitive pharmaceutical desarrollo company."
RudaCure is targeting an IPO by 2027 in the mid-to-long term. To this end, la empresa is concentrating all its capabilities on generating I+D logros through successful ensayo clínicos and global transferencia de tecnologías. Through its presence at Incheon Startup Park and its New York office in the US, la empresa is building a global cooperación network and laying the foundation for crecimiento into a world-class empresa farmacéutica.
With its sede central in Songdo, Yeonsu-gu, Incheon and its investigación center in Gasan, Geumcheon-gu, Seoul, RudaCure contributes to local job creation and economic desarrollo while establishing itself as a socially responsible company through the adoption of eco-friendly drug fabricación tecnología and sustainable management practices.
